SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Feb 13 (Reuters) - Softbank-backed (9434.T), opens new tab genetic test maker Invitae (NVTA.PK), opens new tab said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy ...

Invitae boosted its genetic testing menu with a new test for the diagnosis of spinal muscular atrophy, the second-leading genetic disease in infants. The test provides “significant improvements” over ...

Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price ...

Invitae is scaling up counseling services after recently signing a contract with Cigna to bring its tests in-network, completing the company’s collection of major commercial health plans and accessing ...

San Francisco-based genetic testing company Invitae has rolled out a one-price-fits-all payment model for its range of tests, charging a set $475 for any test for patients who don’t go through their ...

BOSTON--(BUSINESS WIRE)--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation ...